Shimadzu supports drug discovery

July 6, 2012

LCGC Europe eNews

LCGC Europe eNews-07-06-2012, Volume 0, Issue 0

Shimadzu has announced that, in partnership with the Sugiyama Laboratory within the RIKEN Innovation Centre of the RIKEN Research Cluster for Innovation, it has started research on quantitative analysis methods using LC–MS–MS to support drug discovery using microdosing.

Shimadzu has announced that, in partnership with the Sugiyama Laboratory within the RIKEN Innovation Centre of the RIKEN Research Cluster for Innovation, it has started research on quantitative analysis methods using LC–MS–MS to support drug discovery using microdosing.

The RIKEN Innovation Centre invited Professor Yuichi Sugiyama, PhD, of the Department of Molecular Pharmacokinetics, Graduate School of Pharmaceutical Sciences at the University of Tokyo, Tokyo, Japan, to establish the Sugiyama Laboratory for the purpose of researching a system that provides comprehensive support for drug discovery by enabling in vitro and in vivo prediction of pharmacokinetics, efficacy and toxicity, prediction of interactions between drugs, variations between individuals or different pathologies.

Shimadzu has joined a total of 25 companies investing capital in establishing the Sugiyama Laboratory. In addition, Shimadzu has started developing an application system using its LC–MS system and high-sensitivity separation technology for clinical trials of microdosing and studies of cassette dosing.

For more information please visit ref="http://www.shimadzu.com/an/">www.shimadzu.com